The cross-over study of the usefulness of atrial antitachycardia pacing for atrial tachy-arrhythmia in patients implanted with cardiac devices

The cross-over study of the usefulness of atrial antitachycardia pacing for atrial tachy-arrhythmia in patients implanted with cardiac devices - The comparison of the usefulness of atrial antitachycardia pacing in patients with cardiac devices

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019239

Enrollment

100

Registered

2015-10-05

Start date

2015-10-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bradyarrhythmia Tachyarrhythmia

Interventions

Devices equipped atrial anti-tachycardia pacing: pacemaker (Medtronic: Advisa DR, Advisa MRI DR), implantable cardioverter defibrillator (ICD) (Medtronic: Virtuoso-Secura Protecta &amp

middot

Evera DR) or cardiac resynchronization therapy (CRT-D and CRT-P) (Medtronic: Concerto Consulta Protecta Viva). Anti-tachycardia pacing therapy ON for 6 months-&gt

OFF for 6month Devices equipped atrial anti-tachycardia pacing: pacemaker (Medtronic: Advisa DR, Advisa MRI DR), implantable cardioverter defibrillator (ICD) (Medtronic: Virtuoso-Secura Protecta &a

Evera DR) or cardiac resynchronization therapy (CRT-D and CRT-P) (Medtronic: Concerto Consulta Protecta Viva). Anti-tachycardia pacing therapy OFF for 6 months-&gt

ON for 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients implanted with Medtronic pacemaker or ICD implantation with atrial ATP function 2. Patients age 20 years of age or older , male and female 3. Implantation was based on JCS guildeline

Exclusion criteria

Exclusion criteria: 1. Patients less than 20 years old 2. Patients who did not wish to participate in this study 3. Patients whom physician has determined the participation is difficult

Design outcomes

Primary

Measure	Time frame
Incidence of atrial fibrillation, efficacy of anti-tachycardia pacing at 6 month after intervention	—

Secondary

Measure	Time frame
Appropriate ICD/CRT-D therapy within two years after the registration (shock therapy and ATP therapy) In the case of CRT-P , the presence or absence of sustained ventricular tachycardia or ventricular fibrillation The presence or absence of inappropriate shock therapy Prognosis after implantation (death and cause, hospitalization for heart failure, unscheduled hospitalization )	—

Countries

Japan

Contacts

Public ContactYoshiyasu Aizawa

Keio University School of Medicine Department of Cardiology

yoshiyaaizawa-circ@umin.ac.jp03-5363-3928

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026